- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00926055
Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
March 17, 2015 updated by: Korea University
Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.
Therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using FDG-PET.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 152-050
- Korea University Guro
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- hsCRP > 2 mg/L and LDL cholesterol > 130 mm/dL
Exclusion Criteria:
- history of cardiovascular disease
- diabetes
- uncontrolled hypertension
- active infection
- previous anti-hyperlipidemic agents within 6 months
- previous steroid or anti-inflammatory agents within 6 months
- liver disease
- renal disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control
|
|
ACTIVE_COMPARATOR: Ezetimibe
|
Ezetrol - 10 mg once daily for 3 months
|
EXPERIMENTAL: Ezetimibe/Simvastatin
|
Vytorin - 10/20 mg once daily for 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The difference of FDG uptake quantified by measuring the standardized uptake value (SUV) corrected for body weight according to the treatment groups
Time Frame: 3 months later
|
3 months later
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (ANTICIPATED)
September 1, 2012
Study Registration Dates
First Submitted
June 22, 2009
First Submitted That Met QC Criteria
June 22, 2009
First Posted (ESTIMATE)
June 23, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
March 18, 2015
Last Update Submitted That Met QC Criteria
March 17, 2015
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
- Ezetimibe
- Ezetimibe, Simvastatin Drug Combination
Other Study ID Numbers
- R01-2007-000-20546-0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on Ezetrol (Ezetimibe)
-
University Medicine GreifswaldCompletedPharmacokinetics | Pharmacodynamics | Drug Interactions | Intestinal Transporter ExpressionGermany
-
NVP HealthcareCompleted
-
Cao YuRecruiting
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
University Medicine GreifswaldCompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug InteractionsGermany
-
Chong Kun Dang PharmaceuticalCompleted
-
Medical University of GrazCompletedFluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular RiskHypercholesterolemiaAustria
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
University Medicine GreifswaldCompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug InteractionsGermany
-
University Hospital FreiburgEssex Pharma GmbHCompletedHypercholesterolemia | Diabetes Mellitus Type 2Germany